Skip to main content
Equibles
PBLS logo

PBLS · Parabilis Medicines, Inc. · Financials

Track PBLS — free

Use PBLS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PBLS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$30.55 -1.74 (-5.39%) At close · Oct 1
Russell 2000 member Rebalance outlook locked
Market Cap
$3.85B
Shares
123.53M
Volume · Oct 1 885.86K Avg daily vol (3M) 640.73K

Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.

Pull these statements through the financial statements API or MCP →

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow All Metrics
Annual Quarterly
No structured figures reported for this view yet.

Debt Profile

Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.

Debt data is being processed. Please check back later.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue
—
Peer median 7.46×
EV/EBIT
—
Peer median 20.27×
P/E (TTM)
—
Peer median 18.23×

Peer medians compare against the 197 similar-size Biotechnology companies (of 532 listed).

Key facts CIK 1657677 CUSIP 698955101 Visit website Investor relations